Abstract
The global pandemic of type 2 diabetes mellitus (T2DM) is an enormous clinical and socioeconomic burden. Biguanides and DPP-4 inhibitors (DPP-4i) are the most commonly used therapies in Japanese T2DM patients. When glycemic control is not adequate despite combination of these drugs, there is no consensus on the next step drug. Systematic reviews and meta-analyses of previous trials have indicated that glycemic control with triple combination therapies yields similar results. Thus, beneficial effects on cardiovascular risk factors may be important. The present study was designed to evaluate body fat percentage and several insulin resistance parameters after addition of tofogliflozin or glimepiride to the regimens of patients being treated with metformin and a DPP-4 inhibitor but failing to attain adequate blood glucose control. Sodium glucose cotransporter-2 inhibitor, tofogliflozin versus glimepiride, comparative trial in patients with type 2 diabetes on body composition is an ongoing, multicenter, prospective, randomized, open-label, parallel-group trial. T2DM patients treated with metformin/DPP-4 inhibitor dual therapy have been recruited and randomly assigned to 20 mg/day tofogliflozin (n = 32) or 0.5 mg/day glimepiride (n =...Continue Reading
References
Jan 28, 2003·Diabetes Care·Taku TsunekawaAkihisa Iguchi
Mar 28, 2008·Pharmacotherapy·Krystal L EdwardsJessica Fields
Jan 22, 2009·Metabolism: Clinical and Experimental·Takahiro ArakiYoshiki Nishizawa
Jan 5, 2010·Diabetes Research and Clinical Practice·Dan-yan XuXiao-mei Xie
Jan 25, 2011·Diabetes Research and Clinical Practice·Naoto KatakamiYoshimitsu Yamasaki
Aug 6, 2011·Diabetes Care·Michael A NauckShamik J Parikh
Aug 13, 2011·Journal of Human Hypertension·J BlacherM E Safar
Mar 14, 2012·The Journal of Pharmacology and Experimental Therapeutics·Masayuki SuzukiSachiya Ikeda
Jul 16, 2013·Lancet·William T CefaluGary Meininger
Feb 12, 2014·Expert Opinion on Pharmacotherapy·Yukio TanizawaUNKNOWN Tofogliflozin 004 and 005 Study group
Apr 1, 2014·Cardiovascular Diabetology·Kohei KakuUNKNOWN Tofogliflozin 003 Study Group
Jun 21, 2014·The Lancet. Diabetes & Endocrinology·Martin RidderstråleUNKNOWN EMPA-REG H2H-SU trial investigators
Aug 30, 2014·Endocrine Journal·Rieko UmayaharaTatsuhide Inoue
May 31, 2015·Diabetes Research and Clinical Practice·Suguru YamaguchiHisamitsu Ishihara
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Dec 15, 2015·PeerJ·Martin J DownesErika Turkstra
Dec 25, 2015·Current Medical Research and Opinion·G Lozano-OrtegaJ Mukherjee
Mar 24, 2016·Postgraduate Medicine·Lawrence BlondeGary Meininger
Jun 21, 2016·Diabetes Research and Clinical Practice·Crystal Man Ying LeeStephen Colagiuri
Jun 23, 2016·Journal of Diabetes Investigation·Azuma KanatsukaAtsuyoshi Yuhara
Aug 24, 2016·Journal of Diabetes Investigation·Makito TanabeToshihiko Yanase
Oct 30, 2016·Journal of Physiological Anthropology·Mie IzumiToshio Moritani
May 20, 2017·Circulation·Mikhail KosiborodUNKNOWN CVD-REAL Investigators and Study Group*
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Aug 5, 2017·Expert Opinion on Pharmacotherapy·Akio OhtaYasushi Tanaka
Sep 16, 2017·Current Therapeutic Research, Clinical and Experimental·Hiroshi TobitaYoshikazu Kinoshita
Jan 10, 2018·Diabetes, Obesity & Metabolism·Ren MatsubaYasushi Tanaka